Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease

Inclusion Criteria: * Adult patients (≥18 years) with documented ASCVD defined as at least one of the following: * Coronary artery disease (CAD): 1. Previous or recent documented type I myocardial infarction \*(if not specified, will be assumed as type I) 2. History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery) 3. History of obstructive CAD (\>50% stenosis) documented by coronary computed tomography (CT) or conventional angiography * Peripheral arterial disease (PAD): 1. Previous or recent acute ischemic limb event (\>7 days prior) 2. History of previous endovascular/surgical lower or upper extremities revascularization for an atherosclerotic cause 3. History of ulcer or lower extremities amputation due to ASCVD. * Carotid arterial diseases: 1. History of previous endovascular/surgical carotid artery revascularization for atherosclerotic causes 2. History of \> 50% carotid artery stenosis based on documented imaging tests (Duplex US, CT angiography, magnetic resonance angiography, or conventional angiography) * Ischemic stroke: 1. History of recent or previous documented ischemic stroke not due to atrial fibrillation, endocarditis, or systemic hypoperfusion/hypotension, being treated with low-dose aspirin * Inhabitant of Tehran province * Willing to participate and able to provide written informed consent Exclusion Criteria: * Being within 72 days of acute/unstable atherosclerotic cardiovascular events (acute myocardial infarction, acute limb event, and acute ischemic stroke), or within 72 hours of revascularization. * Patients receiving triple antithrombotic therapy * History of upper gastrointestinal bleeding within the past 30 days * History of intracranial hemorrhage within the past 30 days * End-stage kidney disease with estimated creatinine clearance \< 15 mL/min, or undergoing hemodialysis or peritoneal dialysis * Known comorbidities associated with poor prognosis (e.g., metastatic cancer) in conjunction with an estimated life expectancy of less than one year according to the treating clinician * Any other conditions that make the participants unsuitable for recruitment or follow-up (e.g., illiteracy) * Not having aspirin as part of the planned durable treatment regimen * Inability to receive/read text messages/phone calls by personal mobile phone (or that of a caregiver who lives with the patient and is willing to relay messages) * The full list of exclusion criteria is provided in the study protocol